128 related articles for article (PubMed ID: 14692719)
1. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
[No Abstract] [Full Text] [Related]
2. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
Strumberg D; Voliotis D; Moeller JG; Hilger RA; Richly H; Kredtke S; Beling C; Scheulen ME; Seeber S
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):580-1. PubMed ID: 12503822
[No Abstract] [Full Text] [Related]
3. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Kredtke S; Voliotis D; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):620-1. PubMed ID: 14692720
[No Abstract] [Full Text] [Related]
4. Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Hilger RA; Kredtke S; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):648-9. PubMed ID: 15598034
[No Abstract] [Full Text] [Related]
5. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
Heim M; Sharifi M; Hilger RA; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):616-7. PubMed ID: 14692718
[No Abstract] [Full Text] [Related]
6. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
[TBL] [Abstract][Full Text] [Related]
7. BAY 43-9006: preclinical data.
Wilhelm S; Chien DS
Curr Pharm Des; 2002; 8(25):2255-7. PubMed ID: 12369853
[TBL] [Abstract][Full Text] [Related]
8. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.
Hilger RA; Kredke S; Hedley D; Moeller JG; Bauer RJ; Stellberg W; Seeber S; Scheulen ME; Strumberg D
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):567-8. PubMed ID: 12503816
[No Abstract] [Full Text] [Related]
9. Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.
Clin Colorectal Cancer; 2003 May; 3(1):16-8. PubMed ID: 12777188
[No Abstract] [Full Text] [Related]
10. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
11. BAY 43-9006: early clinical data in patients with advanced solid malignancies.
Hotte SJ; Hirte HW
Curr Pharm Des; 2002; 8(25):2249-53. PubMed ID: 12369852
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib (BAY 43-9006): review of clinical development.
Ng R; Chen EX
Curr Clin Pharmacol; 2006 Sep; 1(3):223-8. PubMed ID: 18666747
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
[TBL] [Abstract][Full Text] [Related]
14. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
[TBL] [Abstract][Full Text] [Related]
15. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
16. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
17. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and development of novel camptothecin drugs.
Liew ST; Yang LX
Curr Pharm Des; 2008; 14(11):1078-97. PubMed ID: 18473856
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
20. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]